CTP-499

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526624

CAS#: 1268605-91-9

Description: CTP-499 is a selective PDE inhibitor and deuterium-containing agent that slows the progression of type 2 diabetic kidney disease in patients with macroalbuminuria. CTP-499 is an HDX analog and a pentoxifylline metabolite. Initial testing showed that CTP-499 slowed the negative processes in diabetic kidney disease. Concert is developing the agent as a complementary treatment along with the standard of care, angiotensin modulation with an ACEi or ARB.

Chemical Structure

img
CTP-499
CAS# 1268605-91-9
Instruction

Theoretical Analysis

MedKoo Cat#: 526624
Name: CTP-499
CAS#: 1268605-91-9
Chemical Formula: C13H15D5N4O3
Exact Mass: 285.18
Molecular Weight: 285.359
Elemental Analysis: C, 54.72; H, 8.83; N, 19.63; O, 16.82

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: CTP-499; CTP 499; CTP499.

IUPAC/Chemical Name: (S)-1-(5-hydroxyhexyl-4,4,6,6,6-d5)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione

InChi Key: NSMXQKNUPPXBRG-WHPHVCHMSA-N

InChi Code: InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m0/s1/i1D3,6D2

SMILES Code: O=C(N1CCCC([2H])([2H])[C@@H](O)C([2H])([2H])[2H])N(C)C2=C(N(C)C=N2)C1=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 285.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Martín-Cleary C, Ruiz-Ortega M,
Egido J, Navarro-González JF, Ortiz A, Fernandez-Fernandez B. Horizon 2020 in
Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top
of Renin Angiotensin System Blockade. J Clin Med. 2015 Jun 18;4(6):1325-47. doi:
10.3390/jcm4061325. Review. PubMed PMID: 26239562; PubMed Central PMCID:
PMC4485003.


2: Tang X, Bridson G, Ke J, Wu L, Erol H, Graham P, Lin CH, Braman V, Zhao H, Liu
JF, Lin ZJ, Cheng C. Quantitative analyses of CTP-499 and five major metabolites
by core-structure analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2014
Jul 15;963:1-9. doi: 10.1016/j.jchromb.2014.05.043. Epub 2014 May 28. PubMed
PMID: 24927417.


3: Braman V, Graham P, Cheng C, Turnquist D, Harnett M, Sabounjian L, Shipley J.
A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug
Candidate for Diabetic Nephropathy. Clin Pharmacol Drug Dev. 2013 Jan;2(1):53-66.
doi: 10.1002/cpdd.3. Epub 2013 Feb 21. PubMed PMID: 27121560.